← FDA DRUG APPROVALS

FDA ANDA · ANDA079182

OMEPRAZOLE/SODIUM BICARBONATE

omeprazole

Sponsor: STRIDES PHARMA INTL

APPLICATION
ANDA079182
TYPE
ANDA
ORIGINAL APPROVAL
2013-04-19
LATEST ACTION
2023-12-27
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

OMEPRAZOLE AND SODIUM BICARBONATEPrescription
OMEPRAZOLE 40MG/PACKET, SODIUM BICARBONATE 1.68GM/PACKET · FOR SUSPENSION · ORAL
OMEPRAZOLE AND SODIUM BICARBONATEPrescription
OMEPRAZOLE 20MG/PACKET, SODIUM BICARBONATE 1.68GM/PACKET · FOR SUSPENSION · ORAL

Approval history

2023-12-27Labeling · Supplement 10 · standardAP
2023-12-27Labeling · Supplement 7 · standardAP
2020-08-05Labeling · Supplement 4 · standardAP
2015-04-09Labeling · Supplement 2 · standardAP
2013-04-19OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →